Express News | Lyell Immunopharma Announces Oral Presentation of New Clinical Data From the Phase 1/2 Trial of Lyl314 for the Treatment of Large B-Cell Lymphoma at the International Conference on Malignant Lymphoma (Icml) 2025
Lyell Immunopharma Announces Oral Presentation of New Clinical Data From the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
H.C. Wainwright Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $1
Express News | HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
Lyell Immunopharma Analyst Ratings
Express News | Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation For LYL314 In Treatment Of Relapsed And/Or Refractory Large B-Cell Lymphoma
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed And/or Refractory Large B-Cell Lymphoma
Director's Bold Move: Major Stock Purchase in Lyell Immunopharma!
Insider Purchase: Director at $LYEL Buys 35,640 Shares
Lyell Immunopharma to Cut Jobs, Close West Hills Plant
Lyell Immunopharma's LyFE Center Begins IMPT-314 Production
Express News | Lyell Immunopharma Inc: Reiterates Its Financial Guidance
Express News | Lyell Immunopharma Inc - Lyfe Manufacturing Center Producing Impt-314 for Phase 1/2 Trial - SEC Filing
Express News | Lyell Immunopharma Inc - Expects $3M-$4M Expenses From Workforce Reduction - SEC Filing
Express News | Lyell Immunopharma Inc - to Close West Hills Manufacturing Facility - SEC Filing
BofA Securities Maintains Lyell Immunopharma(LYEL.US) With Sell Rating
Bank of America Securities Keeps Their Sell Rating on Lyell Immunopharma (LYEL)
Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report
Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock
Chief Financial Officer of Lyell Immunopharma Picks Up 989% More Stock